Keywords: Mylan, Shionogi, Andrx, Fortamet, Patent settlement, Merck & Co, Luminex, Alzheimer's diagnostic

Mylan settles with Shionogi and Andrx over Fortamet; Merck & Co diagnostics deal with Luminex

Article | 14 March 2013

Print This

US generic drugmaker Mylan (Nasdaq: MYL) has entered into a settlement agreement with Japan’s Shionogi (TYO: 4507) and privately-held ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in